Our next panel, “Launching on Society: Commercial Names with New & Disruptive Technologies,” featured Shameze Rampertab, EVP, CFO of Asensus Surgical, C. Randal Mills, Ph.D., President & CEO of Aziyo Biologics, Inc., and Lishan Aklog, MD, Chairman & CEO of PAVmed Inc. The panel was moderated by Cantor’s Ross Osborn, CFA.

• Asensus discussed how its robotic system, Senhance, differs from the market leader in that it is designed for laparoscopic surgeons and has artificial intelligence capabilities, such as digital tagging and 3D point-to-point measurement. This gives surgeons tools and insights they have never had with traditional laparoscopic surgery or other robotic systems

• Aziyo highlighted the benefits of the company’s CanGaroo envelope relative to the other offering currently on the market and how the inclusion of antibiotics will further enhance it. Notably, Aziyo has submitted a 510(k) application for the company’s next generation offering, CanGaroo RM, and anticipates a FH23 launch

• PavMed walked attendees through the basis for the company’s IPO of Lucid Diagnostics and the company’s pipeline of offerings in detail, including Veris Health, which is on-track to launch this year

#Cantor #Cantorfitzgerald #Cantorhealthcare #Cantorconferenceseries #Dermatology #Opthalmology #Medtech #Diagnostic